Keyphrases
Receptor Agonist
100%
Mini
100%
Cardiovascular Events
100%
A1 Receptor
100%
Glucagon-like
100%
Major Adverse Cardiovascular Events
40%
Cardiovascular Protective
40%
Type 2 Diabetes Mellitus (T2DM)
20%
Glucagon-like peptide-1 (GLP-1)
20%
Possible Mechanisms
20%
Diabetic Patients
20%
Standard of Care
20%
Cardiovascular Risk
20%
Disease Process
20%
Safety Profile
20%
Surrogate Marker
20%
Countries Worldwide
20%
Atherogenic Index
20%
Mediation Analysis
20%
Antihyperglycemic
20%
Cardiovascular Outcome Trials
20%
Antiatherogenic
20%
Atherosclerotic Cardiovascular Disease (ASCVD)
20%
Medicine and Dentistry
Cardiovascular System
100%
Glucagon-Like Peptide-1 Agonist
100%
Cardiovascular Disease
40%
Diabetes Mellitus
20%
Glucagon Like Peptide 1
20%
Maturity Onset Diabetes of the Young
20%
Cardiovascular Risk
20%
Disease Process
20%
Disease Marker
20%
Antidiabetic Activity
20%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 1 Receptor Agonist
100%
Cardiovascular Disease
40%
Coronary Artery Atherosclerosis
20%
Glucagon-Like Peptide-1
20%
Cardiovascular Risk
20%
Disease Marker
20%
Diabetes Mellitus
20%
Non Insulin Dependent Diabetes Mellitus
20%
Biochemistry, Genetics and Molecular Biology
Receptor Agonists
100%
Glucagon-Like Peptide 1 Receptor
100%
Antidiabetic Activity
20%
Glucagon-Like Peptide-1
20%
Chemistry
Glucagon-Like Peptide-1 Receptor Agonist
100%
Protective
40%
Anti Atherogenis
20%
Hyperglycemic
20%